cated. There is also a unique susceptibility of pancreas allograft to the diabetogenicity of immunosuppressants, and the transplanted pancreas continues to remain susceptible to recurrence of autoimmune disease [2,3]. Most pancreas transplant centers traditionally have employed quadruple drug immuno

Zhenshun Song,Ajai Khanna,Nilesh H. Patel,Rahul M. Jindal
2001-01-01
Abstract:There is firm evidence that tacrolimus is superior to cyclosporine A, whereas mycophenolate mofetil is routinely used by most centers for pancreatic transplants. It is possible that the superior results seen with tacrolimus may reflect the addition of mycophenolate mofetil to the therapeutic regimen, rather than the use of tacrolimus per se. It also is becoming clear that induction with anti–T-cell antibodies may not be necessary in all pancreatic transplants. Newer anti–interleukin2 antibodies have been shown to be as effective as traditional antibodies. The lessons learned from clinical trials in recipients of kidney transplants are now being applied to that of pancreas transplants, in particular, steroid withdrawal. Safety of percutaneous pancreatic biopsy has been demonstrated as an effective guide to immunosuppressive therapy. Curr Opin Organ
What problem does this paper attempt to address?